CClinicalTrials.gg
Status unknownNCT04711876Bledi-CytokineUpdated Jan 15, 2021

Characterization of Cytokines Expression During Enterovirus Meningitis in Paediatric Populations.

An observational study in Meningitis Enterovirus, sponsored by University Hospital, Clermont-Ferrand. Status unknown at 1 site in France. Open to participants aged 1 Day to 16 Years. Per ClinicalTrials.gov, last updated 2021-01-15.

Sponsored by University Hospital, Clermont-Ferrand · Observational

The sponsor has not verified this record recently (last verified Jan 2021), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
180
Ages
1 Day to 16 Years
Sex
All
01

Study summary

Enteroviruses (EV) are the most frequent cause of acute meningitis in the paediatric population. Detection of enterovirus in cerebrospinal fluid (CSF) specimens by Polymerase Chain Reaction (PCR) is the gold standard diagnostic test. Recently, our laboratory published the BLEDI study which highlighted the interest of detecting EV in the blood of the paediatric population : (i) EV was found in more than a quarter of cases in the blood of infants admitted to hospital with isolated fever and (ii) detection of EV was more frequent in the blood than in CSF in neonates and infants with isolated fever, sepsis or meningitis. However, the pathophysiology of EV infections is poorly understood and little work has been done on the inflammatory response to these infections. In EV meningitis, the inflammatory response has been studied primarily in children infected with enterovirus A71 (EV-A71). Indeed, in these children, inappropriate cytokine secretion (cytokine storm) leads to severe neurological and cardiopulmonary damage, which can progress to death. The study of the inflammatory response during meningitis due to other types of EV remains poorly

The objective of BLEDI-CYTOKINES (ancillary study of the BLEDI study) is to study the inflammatory response during EV meningitis in neonates, infants and children, as assessed by cytokine levels in blood and cerebrospinal fluid, by comparing case-controls from an existing cohort.

Read the detailed description

EVs are characterized by their high genetic variability, with more than 120 types described to date. They are involved in mild infections, such as febrile syndromes that may be associated with respiratory and cutaneous manifestations. However, these viruses are also involved in more severe infections of the nervous system. In children infected with EV-A71, which causes mild epidemics of foot-and-mouth disease, inappropriate cytokine secretion (cytokine storm) leads to severe neurological and cardiopulmonary complications that can progress to death in children (\<5 years of age) in Asia. Many studies have focused on the inflammatory response to EV-A71 infections: some cytokines (Tumor Necrose Factor (TNF), INterFeron (INF), InterLeukine (IL)1, IL6, IL10, eotaxin,...) dosed in CSF have been associated with severe EV-A71 infections (2,5,6). Recently, a Japanese study showed an overexpression of IL-6 in the blood of children with EV-A71 foot-hand-mouth syndrome. The authors defined that a level of IL-6 ≥ 66 pg/mL could be a prognostic marker of progression to aseptic meningitis (6). In EV (other than EV-A71) meningitis, pro-inflammatory cytokines such as IL6, IL8, and INF are produced in the acute phase in CSF to control the infection, and then they decline and anti-inflammatory cytokines such as IL10 are synthesized (7). In addition, studies have shown that the production of some cytokines is greater in severe EV infections: for example, the production of IL4 and IL5 is greater in EV encephalitis than in EV skin infections (8).

However, there are very few comparative studies of cytokine expression in blood and CSF. In addition, little work has been done to study cytokine expression in meningitis due to EV other than EV-A71. In young children, these meningitis may also be complicated by encephalitis, myelitis, and even flaccid paralysis (including poliomyelitis) (2-4). The pathophysiology of these severe EV infections is currently unknown. In addition, no preventive vaccine is available against these infections (other than polio vaccine), nor are there effective curative antivirals for severe EV infections.

02

Conditions studied

  • Meningitis Enterovirus

Keywords

  • Enterovirus infection
  • Cytokine expression
  • Paediatric population
  • Blood
  • Cerebrospinal fluid
  • Inflammatory
  • Meningitis viral
03

In context

Enterovirus Infections

47 studies on the registry are indexed under Enterovirus Infections; 5 are open to participants now.

This study's planned enrollment of 180 is below the median of 214 across 14 observational studies indexed under Enterovirus Infections.

Browse Enterovirus Infections studies →

Lead sponsor

University Hospital, Clermont-Ferrand is the lead sponsor of 841 studies on the registry; 178 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Day to 16 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Paediatric patient with suspicion of meningitis

Inclusion criteria

  • Patients with proven enterovirus meningitis (RT- PCR EV positive)
  • Control patients admitted for suspected meningitis infection but for whom the bacteriological (LCS culture/ blood culture negative) and virological diagnosis (testing for enteroviruses (RT-PCR negative) and parechoviruses (viruses responsible for symptoms similar to those of EVs) is negative

Exclusion criteria

Exclusion Criteria:

For patients with EV meningitis, we will exclude:

  • patients with co-infection
  • haemorrhagic CSF samples
  • samples (CSF or blood) for which we do not have access to EV viral load results
  • samples (CSF or blood) for which we do not have access to the EV genotyping results

For patients in the control group (without EV meningitis), we will exclude :

  • Samples from patients with an infection (viral or bacterial) in the control group.
  • haemorrhagic CSF samples
  • CSF samples with pleocytosis (presence of CSF leucocytes).
  • Blood samples with high CRP (CRP>15mg/L).
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
180 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Test group with enterovirus meningitis

    Level of Cytokine in blood and CSF for Patient with RT-PCR-EV +

    Biological: Cytokine level in blood and CSF

  • Control group with no enterovirus meningitis

    Level of Cytokine in blood and CSF for Patient with RT-PCR-EV -

    Biological: Cytokine level in blood and CSF

Interventions

  • BiologicalCytokine level in blood and CSF

    Measure of cytokine level

06

What researchers measure

Primary outcomes

  1. Expression of cytokine in blood

    Level of cytokine in blood

    Time frame: Day 1

  2. Expression of cytokine in cerebrospinal fluid

    Level of cytokine in cerebrospinal fluid

    Time frame: Day 1

07

Study locations

1 site
  • University Hospital, Clermont Ferrand
    Clermont-Ferrand, Aura 63000, France
    • Christine ARCHIMBAUD · Principal investigator
08

References and documents

Publications

  • Lafolie J, Labbe A, L'Honneur AS, Madhi F, Pereira B, Decobert M, Adam MN, Gouraud F, Faibis F, Arditty F, Marque-Juillet S, Guitteny MA, Lagathu G, Verdan M, Rozenberg F, Mirand A, Peigue-Lafeuille H, Henquell C, Bailly JL, Archimbaud C; Blood Enterovirus Diagnosis Infection (BLEDI) in paediatric population study team. Assessment of blood enterovirus PCR testing in paediatric populations with fever without source, sepsis-like disease, or suspected meningitis: a prospective, multicentre, observational cohort study. Lancet Infect Dis. 2018 Dec;18(12):1385-1396. doi: 10.1016/S1473-3099(18)30479-1. Epub 2018 Oct 30. PubMed 30389482 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04711876
Lead sponsor
University Hospital, Clermont-Ferrand
Collaborators
Laboratory of virology, National Enterovirus and parechovirus Reference Center, University Hospital of Clermont-Ferrand
Responsible party
Sponsor
First posted
Jan 15, 2021
Start date
Apr 1, 2021 (estimated)
Primary completion
Jun 1, 2021 (estimated)
Completion
Jun 1, 2021 (estimated)
Last update
Jan 15, 2021

Study contacts

Lise Laclautre
Contact
promo_interne_drci@chu-clermontferrand.fr
0473754963

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion